- Trials with a EudraCT protocol (42)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
42 result(s) found for: Avidity.
Displaying page 1 of 3.
| EudraCT Number: 2013-001864-50 | Sponsor Protocol Number: IIV-268 | Start Date*: 2013-07-22 |
| Sponsor Name:National Institute for Public Health and the Environment (RIVM, the Netherlands) | ||
| Full Title: Long-term memory immunity against Bordetella pertussis in children 9 years of age who have been vaccinated with acellular pertussis vaccines: effect of an extra preadolescent acellular booster vacc... | ||
| Medical condition: The vaccine administered in this study is used to prevent pertussis caused by the bacterium Bordetella pertussis | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-003804-42 | Sponsor Protocol Number: INCENTIVE-QIV2-EU | Start Date*: 2021-10-04 |
| Sponsor Name:Helse Bergen HF | ||
| Full Title: Immunogenicity, molecular profiling and safety of a marketed quadrivalent influenza vaccine (Vaxigrip Tetra) administered by the intramuscular route in children 3-11 years old | ||
| Medical condition: Immune response to infuenza vaccine in young children | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: NO (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-001638-34 | Sponsor Protocol Number: navaboost | Start Date*: 2006-09-28 |
| Sponsor Name:Health Protection Agency | ||
| Full Title: A phase IV, single group study to evaluate the magnitude of antibody response, its persistence and avidity maturation following meningococcal serogroup C conjugate booster vaccination in older chil... | ||
| Medical condition: Meningococcal Group C Disease | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-000375-13 | Sponsor Protocol Number: LIS-144 | Start Date*: 2011-05-02 |
| Sponsor Name:National Institute of Public Health and Environment (RIVM, the Netherlands) | ||
| Full Title: Study to determine the appropriate age for a second immunization with the Meningococcal C conjugated vaccine. | ||
| Medical condition: The vaccin administered in this study is used to prevent invasive disease caused by Meningococcal serogroup C. | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-004489-23 | Sponsor Protocol Number: NVI-248 | Start Date*: 2008-10-20 |
| Sponsor Name:Netherlands Vaccine Institute | ||
| Full Title: Development of cellular immune response after infant pneumococcal conjugate vaccinations | ||
| Medical condition: Cellular immune response(long term memory) after following the infant immunisation programme with a pneumococcal conjugate vaccine (Prevenar). | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-007235-40 | Sponsor Protocol Number: 2008-007235 | Start Date*: 2009-06-10 |
| Sponsor Name:Department für Pädiatrie, Medizinische Universität Innsbruck | ||
| Full Title: Development of Varicella-zoster virus (VZV)-specific CD4+ T cells on primary VZV infection or vaccination in renal transplant (RTX) recipients and healthy donors | ||
| Medical condition: Patients (aged 24 months to 80 years) listed for renal transplantation | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-005105-20 | Sponsor Protocol Number: V48P4E3 | Start Date*: 2014-11-28 |
| Sponsor Name:Novartis Vaccines and Diagnostics | ||
| Full Title: A phase IV, uncontrolled, open-label, multi-center study in children and adolescents: Evaluation of long-term immunogenicity in subjects boosted with a new pediatric TBE vaccine (free of protein-de... | ||
| Medical condition: Prophylaxis: Tick-borne-encephalitis | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2016-001104-36 | Sponsor Protocol Number: IIV-291 | Start Date*: 2016-06-01 |
| Sponsor Name:RIVM | ||
| Full Title: Immunogenicity and safety study of a third measles mumps rubella (MMR-3) vaccine dose in healthy young adults in The Netherlands | ||
| Medical condition: immunological response to an extra mumps immunization (in healthy volunteers) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-001301-24 | Sponsor Protocol Number: IIV-407 | Start Date*: 2020-03-20 |
| Sponsor Name:National Institute for Public Health and the Environment (RIVM) | ||
| Full Title: ‘Primary and booster meningococcal vaccination in Dutch elderly: study to investigate the immune response and determine functional antibodies after the tetravalent MenACWY-TT conjugate vaccine in t... | ||
| Medical condition: The tetravelent MenACWY-TT vaccin administered in this study is used to prevent invasive disease caused by Meningococcal serogroup A, C, W and Y. | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-000177-25 | Sponsor Protocol Number: ATA129-EBV-205 | Start Date*: 2021-01-04 | |||||||||||
| Sponsor Name:Atara Biotherapeutics, Inc. | |||||||||||||
| Full Title: An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases | |||||||||||||
| Medical condition: • EBV+ primary imunodeficiency lymphoproliferative disease (LPD) • EBV+ LPD in the setting of acquired (non-congenital) immunodeficiency • EBV+ post-transplant LPD involving the central nervous ... | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-003078-28 | Sponsor Protocol Number: IIV-273 | Start Date*: 2013-08-22 |
| Sponsor Name:RIVM | ||
| Full Title: Immunological effect of early extra MMR immunization in infants between 6 and 12 months of age in an outbreak setting | ||
| Medical condition: healthy volunteer (immunological response to early extra measles immunization) | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-001676-21 | Sponsor Protocol Number: V48P7E1 | Start Date*: 2006-08-14 | |||||||||||
| Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG | |||||||||||||
| Full Title: A phase IV, open-label, single-center study in adolescents and adults: Evaluation of immunogenicity and safety of the first booster immunization with Chiron’s TBE vaccine for adults in participants... | |||||||||||||
| Medical condition: TBE prophylaxis | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-002103-15 | Sponsor Protocol Number: VAC-259 | Start Date*: 2011-09-07 |
| Sponsor Name:RIVM | ||
| Full Title: Development of humoral and cellular immune response in infants after pneumococcal conjugate vaccinations with Synflorix® or Prevenar-13® | ||
| Medical condition: Immunity and immune memory after pneumococcal vaccination against S. pneumoniae serotypes present in either Synflorix or Prevenar-13 | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-005090-26 | Sponsor Protocol Number: Kleb4V01 | Start Date*: 2021-06-21 | |||||||||||
| Sponsor Name:LimmaTech Biologics AG | |||||||||||||
| Full Title: Safety and immunogenicity of a Klebsiella pneumoniae tetravalent bioconjugate vaccine (Kleb4V) administered to healthy adults: A FTIH phase I/II randomized and controlled study. | |||||||||||||
| Medical condition: Klebsiella pneumoniae (K. pneumoniae), a gram negative Enterobacteriaceae, is an opportunistic pathogen leading to hospital- and community-acquired infections (urinary tract infections, pneumonia a... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-002383-32 | Sponsor Protocol Number: 997 | Start Date*: 2021-07-02 | ||||||||||||||||
| Sponsor Name:Biotest AG | ||||||||||||||||||
| Full Title: Prevention of maternal-fetal Cytomegalovirus transmission after primary maternal infection with gestational age ≤ 14 weeks – an open-label, single-arm, prospective trial investigating efficacy and ... | ||||||||||||||||||
| Medical condition: Prevention of maternal-fetal cytomegalovirus transmission after primary maternal infection with gestational age ≤ 14 weeks | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2016-003678-42 | Sponsor Protocol Number: IIV-316 | Start Date*: 2017-09-01 |
| Sponsor Name:RIVM [...] | ||
| Full Title: Immunological effects of an acellular pertussis booster vaccination in children, young adults and elderly with different immunisation background. An international study in Finland, the Netherlands... | ||
| Medical condition: Pertussis infection | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) FI (Completed) GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-005091-13 | Sponsor Protocol Number: SMS | Start Date*: 2008-03-06 | |||||||||||
| Sponsor Name:Guy's & St Thomas' NHS Foundation Trust [...] | |||||||||||||
| Full Title: Phase II study of sorafenib in malignant mesothelioma previously treated with platinum-based chemotherapy | |||||||||||||
| Medical condition: Malignant Mesothelioma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-006194-33 | Sponsor Protocol Number: 6096A1-3013-EU | Start Date*: 2009-04-07 | |||||||||||
| Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | |||||||||||||
| Full Title: Revaccination with Pneumococcal Conjugate Vaccine - Characterization of the Immune Response after Polysaccharide (REPLAY) | |||||||||||||
| Medical condition: Invasive pneumococcal disease | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: IS (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-003547-24 | Sponsor Protocol Number: 21CH134 | Start Date*: 2021-08-25 | |||||||||||
| Sponsor Name:CHU de Saint Etienne | |||||||||||||
| Full Title: Factors influencing the COVID-19 vaccine immune response (reactogenicity and immunogenicity) according to age and presence or not of a past history of COVID-19. COVIMMUNAGE study | |||||||||||||
| Medical condition: Volunteer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-002363-22 | Sponsor Protocol Number: IIV-482 | Start Date*: 2021-05-27 |
| Sponsor Name:National Institute for Public Health and the Environment | ||
| Full Title: Vaccination of older persons against Sars-Cov-2 and cellular immunogenicity for long term protection (participating in the Doetinchem Cohort Study) | ||
| Medical condition: SARS-CoV-19, frailty | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
